Traders should monitor for official pricing and closing of the offering, which could lead to short-term volatility. The reverse split and capital raise suggest management is shoring up the balance sheet, but the small offering size and micro-cap status imply high risk. Watch for insider trading patterns and subsequent clinical development updates.
Price Chart
Executive Summary
FibroBiologics' S-1 registration has become effective, allowing the company to proceed with its planned public offering of up to 1,136,363 shares of common stock, pre-funded warrants, and accompanying warrants. The offering is priced at $4.40 per security, with proceeds intended for general corporate purposes, following a 1-for-20 reverse stock split effective March 30, 2026.
Key Facts
- S-1 registration effective as of March 31, 2026, enabling FibroBiologics to begin selling securities in its public offering.
- Offering includes up to 1,136,363 shares of common stock, 1,136,363 pre-funded warrants, and 1,136,363 warrants, priced at $4.40 per unit.
- Company implemented a 1-for-20 reverse stock split effective March 30, 2026, to comply with Nasdaq listing requirements.
- H.C. Wainwright & Co. is acting as exclusive placement agent; no assurance of full sale of offered securities.
- Proceeds will be used for general corporate purposes, including R&D and working capital.
Financial Impact
Up to $5.0 million in gross proceeds if all securities are sold (1,136,363 units × $4.40). Additional potential proceeds of up to $7.5 million from future warrant exercises disclosed in prior S-1.
Risk Factors
- Limited liquidity and high volatility due to micro-cap status (market cap: $5M).
- Dilution risk from potential exercise of up to 2.35 million additional shares underlying warrants.
- No guaranteed sale of all offered securities; placement agent has no firm commitment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001031 |
| Document: 9999999995-26-001031-index.html | 9999999995-26-001031 |
| Document: 9999999995-26-001031.txt | 9999999995-26-001031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers